Back to Search Start Over

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial.

Authors :
Qin, S.
Chan, L.S.
Gu, S.
Bai, Y.
Ren, Z.
Lin, X.
Chen, Z.
Jia, W.
Jin, Y.
Guo, Y.
Sultanbaev, A.V.
Pazgan-Simon, M.
Pisetska, M.
Liang, X.
Chen, C.
Nie, Z.
Wang, L.
Cheng, A-L.
Kaseb, A.
Vogel, A.
Source :
Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1401-S1402. 2p.
Publication Year :
2022

Subjects

Subjects :
*CLINICAL trials
*HEPATOCELLULAR carcinoma
*SORAFENIB

Details

Language :
English
ISSN :
09237534
Volume :
33
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
159078733
Full Text :
https://doi.org/10.1016/j.annonc.2022.08.032
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details